Indevus Jumps Endo Slumps on Plans for $637M Merger
The News Review:
- Indevus Jumps Endo Slumps on Plans for $637M Merger
- Avoiding Urologic Surgery Infections
- ‘I . . . feel like a man again’
- Urodynamix Technologies Ltd. Receives FDA 510(k) Clearance For
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and …
Indevus Jumps Endo Slumps on Plans for $637M Merger
BioWorld nline GA
Indevus CE Glenn Cooper said the deal allows the company to “capture significant value” for its shareholders while also creating new value for patients physicians and shareholders of both companies under Endo’s leadership. “We believe Endo’s proven commercial capabilities targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products” Cooper said. Leerink Swann analyst Gary Nachman said the deal was an “attractive opportunity” in urology for Endo and represented the “first big step” of the company’s new management team to move the firm beyond pain and into new therapeutic areas. Nachman said he also was “encouraged” by the deal for Indevus a company about whose prospects he has been bullish. While Nachman said he previously had valued Indevus at $5 to $6 per share he said the $4. 50 per share price Endo is paying for the firm was “reasonable. “At this point we do not view additional bidders as likely to emerge” Nachman declared.
Avoiding Urologic Surgery Infections
Renal and Urology News NY
4pt;mso-para-margin:0in;mso-para-margin-bottom:. 0001pt;mso-pagination:widow-orphan;font-size:10. 0pt;font-family:”Times New Roman”;mso-fareast-font-family:”Times New Roman”;mso-ansi-language:#0400;mso-fareast-language:#0400;mso-bidi-language:#0400;}An AUA-sponsored panelhas developed a ?Best Practice Statement? to guide antimicrobial prophylaxis The Best Practice Statement on Urologic SurgeryAntimicrobial Prophylaxis wasdeveloped by the American Urological Association (AUA) and published inthe April issue of the Journal of Urology(2008; 179:1379-1390). Correctedtables which added some agents not included in the original publication andprovided some clarifications were published in the November issue ofthe Journal of Urology (2008;180:2262 ? 2263). Additionally the revisedtable was published in the November issue of AUANews (vol. The document is available online at the AUA Web site at.
‘I . . . feel like a man again’
Boston Globe United States
Then the growth plateaus even if more testosterone is added. In 2006 Morgentaler cowrote a study on 345 men with low testosterone. The study – published in the journal Urology and not industry funded – showed prostate cancer risk was higher in men with the lowest testosterone a finding supported by a handful of other small-scale studies using human subjects. That was contrary to findings suggested by the Physicians’ Health Study in 1996 a discrepancy doctors can not fully explain. And last February an analysis of data from 18 studies around the world involving nearly 4000 men with prostate cancer and more than 6000 without showed no correlation between high testosterone levels and cancer risk. The study was published in the Journal of the National Cancer Institute. Understanding the pros and cons of testosterone replacement is not easy.
Urodynamix Technologies Ltd. Receives FDA 510(k) Clearance For
Medical Design nline (press release) PA
Food and Drug Administration to market the UroNIRS 2000 Bladder Monitor System – a second generation non-invasive medical device that uses near infrared spectroscopy (NIRS) to aid in the diagnosis of lower urinary tract symptoms (LUTS) in a urology office setting. UroNIRS 2000 is a standalone device that does not require conventional external or peripheral urodynamics equipment for its operation unlike first generation UroNIRS technology. This will allow Urodynamix to expand distribution of its UroNIRS products into urology office markets targeting the 20 million men in the U. with symptoms of benign prostatic hyperplasia (BPH) many of whom require diagnosis prior to effective treatment. “We are pleased to achieve another major milestone in the execution of our business strategy. The Company has orders in hand and will begin shipments of the uroNIRS 2000 in the first quarter of 2009.
Effect of Selenium and Vitamin E on Risk of Prostate Cancer and …
Journal of American Medical Association (subscription) IL
Anderson Cancer Center Houston; Glickman Urological and Kidney Institute and Taussig Cancer Institute Cleveland Clinic Cleveland hio (Dr Klein); Southwest ncology Group Statistical Center Seattle Washington (Dr Crowley and Mss P. Goodman); Altamira Family Medicine Rio Piedras Puerto Rico (Dr Claudio); London Regional Cancer Program London Health Sciences Center London ntario Canada (Dr Winquist); Department of Urologic Surgery Duke University Medical Center Durham North Carolina (Dr Walther); Department of Urology Mayo Clinic Rochester Minnesota (Dr Lieber); Departments of Epidemiology (Dr Kristal) and Medicine and Cardiology (Dr Probstfield) University of Washington Seattle; Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center University of California Los Angeles (Dr Ganz); Mailman School of Public Health Columbia University New York New York (Dr Santella); Center for Clinical Epidemiology and Evaluation University of British Columbia Vancouver Canada (Mr Jagpal); Chao Family Comprehensive Cancer Center University of California at Irvine range (Dr Meyskens); and Division of Hematology and ncology University of Michigan (Dr Baker) and Southwest ncology Group (Drs Baker and Coltman) Ann Arbor Michigan. Michael Gaziano Robert J.
Related from Indoorenvirons: Cough Medicine Ingredient Could Effectively Treat Prostate Cancer …
Written by admin on January 7th, 2009 with
no comments.
Read more articles on News.